Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
City of Hope Medical Center
mi
from
Duarte, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Loyola University Medical Center
mi
from
Maywood, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Southern Illinois University
mi
from
Springfield, IL
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Maryland Saint Joseph Medical Center
mi
from
Towson, MD
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Maryland Saint Joseph Medical Center
mi
from
Towson, MD
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Michigan
mi
from
Ann Arbor, MI
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Status: Enrolling
Updated:  8/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Status: Enrolling
Updated: 8/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Status: Enrolling
Updated:  8/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Status: Enrolling
Updated: 8/5/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
GTX-RT in Borderline Resectable Pancreatic Cancer
Validation of a Radiation Response Signature in Borderline Resectable Pancreatic Cancer Patients Treated With Induction Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT)
Status: Enrolling
Updated:  8/6/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
GTX-RT in Borderline Resectable Pancreatic Cancer
Validation of a Radiation Response Signature in Borderline Resectable Pancreatic Cancer Patients Treated With Induction Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT)
Status: Enrolling
Updated: 8/6/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
ABC294640 in Treating Patients With Advanced Solid Tumors
A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/19/2015
Medical University of South Carolina
mi
from
Charleston, SC
ABC294640 in Treating Patients With Advanced Solid Tumors
A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/19/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
A Randomized Phase II Study of Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy for Patients With Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  8/19/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
A Randomized Phase II Study of Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy for Patients With Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 8/19/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bupropion in Helping Adults Stop Smoking
A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation
Status: Enrolling
Updated:  8/27/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Bupropion in Helping Adults Stop Smoking
A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation
Status: Enrolling
Updated: 8/27/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/28/2015
Rush University Medical Center
mi
from
Chicago, IL
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/28/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated:  8/28/2015
University of Michigan
mi
from
Ann Arbor, MI
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Status: Enrolling
Updated: 8/28/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
University of California, San Diego Medical Center
mi
from
La Jolla, CA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
University of California, San Diego Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
University of Miami
mi
from
Miami, FL
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Medical Oncology LLC
mi
from
Baton Rouge, LA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Medical Oncology LLC
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Annapolis Oncology Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Dana-Farber Cancer Center
mi
from
Boston, MA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Virginia G. Piper Cancer Center
mi
from
Minneapolis, MN
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Virginia G. Piper Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Regional Oncology Center
mi
from
Syracuse, NY
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Regional Oncology Center
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Kaiser Permanente Northwest Region Oncology Hematology
mi
from
Portland, OR
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Kaiser Permanente Northwest Region Oncology Hematology
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Baptist Regional Cancer Center
mi
from
Knoxville, TN
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Baptist Regional Cancer Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Vanderbilt University Medical Center, Div. of Medical Oncology
mi
from
Nashville, TN
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Vanderbilt University Medical Center, Div. of Medical Oncology
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic
mi
from
Lynchburg, VA
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic
mi
from
Lynchburg, VA
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  8/31/2015
Cross Cancer Institute
mi
from
Edmonton,
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 8/31/2015
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Southern California Permanente Medical Group
mi
from
San Diego, CA
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Southern California Permanente Medical Group
mi
from
San Diego, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Sharp Memorial Hospital
mi
from
San Diego, CA
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Kaiser Permanente
mi
from
Vallejo, CA
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Kaiser Permanente
mi
from
Vallejo, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Cancer Center of Central Connecticut
mi
from
Southington, CT
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Cancer Center of Central Connecticut
mi
from
Southington, CT
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Connecticut Oncology & Hematology
mi
from
Torrington, CT
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Connecticut Oncology & Hematology
mi
from
Torrington, CT
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Palm Beach Institute of Hematology and Oncology
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Hematology Oncology Associates of the Palm Beaches
mi
from
Lake Worth, FL
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Hematology Oncology Associates of the Palm Beaches
mi
from
Lake Worth, FL
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated:  9/4/2015
Hematology Oncology Associates of Illinois
mi
from
Skokie, IL
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Status: Enrolling
Updated: 9/4/2015
Hematology Oncology Associates of Illinois
mi
from
Skokie, IL
Click here to add this to my saved trials